Pharmaron Beijing Co., Ltd. (3759.HK)

8.450 -0.140 (-1.63%) At close: 04:08PM HKT

Pharmaron Beijing Co., Ltd.

Building 1
8th floor No. 6 Taihe Road Beijing Economic and Technological Development Zon
Beijing 100176
China
86 10 5733 0087
https://www.pharmaron.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 20,295

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Boliang Lou Ph.D.	Chairman & CEO	2.37M	N/A	1963
Mr. Xiaoqiang Lou EMBA	Co-Founder, President, COO & Executive Director	2.05M	N/A	1968
Ms. Bei Zheng M.A, M.A.	Executive VP & Executive Director	1.72M	N/A	1967
Mr. Shing Chung Li C.F.A., CPA	CFO & Secretary of the Board	N/A	N/A	1978
Dr. Hua Yang Ph.D.	Chief Scientific Officer & Deputy Manager	N/A	N/A	1962
Dr. Connie Sun Ph.D.	Senior VP & Global Head of Business Development of Small Molecules	N/A	N/A	N/A
Ms. Celina Zhong M.B.A., MBA	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Katherine Lee M.B.A., MBA	Chief Business Officer	N/A	N/A	N/A
Mr. Stephen Lewinton	Senior Vice President of UK Operations	N/A	N/A	N/A
Dr. Jingqi Huang	Senior Vice President of In Vivo Pharmacology	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, rest of Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Preparation Process Development, and Production Services; Clinical Research Services; Macromolecule and Cell, and Gene Therapy Services; and Others. The company offers laboratory chemical services, including medicinal chemistry, synthetic chemistry, analytical and purification chemistry, and computer-aided drug design; bioscience services, such as in vitro and in vivo drug metabolism and pharmacokinetics, in vitro biology and in vivo pharmacology, drug safety evaluation, and US laboratory services; and process development and production, material science/preparation, preparation development and production, and analytical development services. It also provides radiolabeling science and early clinical trial services; clinical trial and clinical research site management services; and macromolecular drug discovery and development, and production services (CDMO), as well as cell and gene therapy laboratory, and gene therapy CDMO services. In addition, the company provides safety assessment, and chemistry, manufacturing, and controls services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Corporate governance

Pharmaron Beijing Co., Ltd.’s ISS governance QualityScore as of 29 June 2024 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.